# GPT Healthcare share price today (GPT Healthcare Ltd, NSE: GPTHEALTH)

> GPT Healthcare share price today: ₹137.66 at the NSE close on 3 November 2026, down 7.4% in a year. GPT Healthcare (NSE: GPTHEALTH) is worth ₹1,127 crore, trades at a P/E of 23.8 and has closed between ₹116.02 and ₹170.49 over the past 52 weeks. > GPT Healthcare Ltd's results are improving, while its P/E is near the low end of its own history over 2.7 years, higher than only 6% of past readings. GPTHEALTH · Hospitals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/gpt-healthcare-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹137.66 (−7.4% in a year)
- P/E: 23.8× (lower than 94% of the last 2.7 years)
- Revenue (Jun 2026): ₹126 Cr (+17.8% on a year ago)
- Profit (Jun 2026): ₹13.0 Cr (+62.5% on a year ago)
- Operating margin: 19.0% (+3.0 points on a year ago)
- ROCE: 20%, FY26
- ROIC: 16.0%, against a 12.0% cost of capital: +4.0 points

The main question: foreign institutions moved −1.7 percentage points over 8 quarters while the business went the other way. ## What is the GPT Healthcare share price today? GPT Healthcare Ltd's share price was ₹137.66 at the close on 3 November 2026. It has been rising for 20 weeks. That is 6.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹116 and ₹170, and at that close it sat 40% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running. Over the last 2.7 years the share price moved −28% while the NIFTY 500 moved +11%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at GPT Healthcare this quarter? Three changes stood out: revenue up on a year earlier for 7 quarters in a row, indian funds and insurers (DIIs) raised their stake for 3 quarters in a row and operating margin up 3 points on a year earlier. 1. Revenue up on a year earlier for 7 quarters in a row In the June 2026 quarter revenue was ₹126 crore, +17.8% on a year earlier. 2. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row From 6.2% to 7.1% of the company by the September 2026 quarter. 3. Operating margin up 3 points on a year earlier 19% in the June 2026 quarter, from 16%. Why: Operating margin rose because prices rose with inflation and the mix of cases changed. Next results: check whether Raipur losses shrink, since new hospital losses pull down company-wide profit. From the earnings call on 28 Sep 2026. ## What are GPT Healthcare's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), GPT Healthcare reported revenue of ₹126 crore, up 17.8% from ₹107 crore a year earlier, and a profit of ₹13.0 crore, up 62.5% from ₹8.00 crore. ### GPT Healthcare results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹126 crore | ₹107 crore | +17.8% |
| Profit | ₹13.0 crore | ₹8.00 crore | +62.5% |
| Earnings per share | ₹1.55 | ₹0.94 | +64.9% |
| Operating margin | 19.0% | 16.0% | +3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). GPT Healthcare's management discussed these results on a call held on 28 September 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the GPT Healthcare share price history? GPT Healthcare closed at ₹137.66 on 3 November 2026, down 7.4% from ₹148.64 a year earlier (31 October 2025). Its highest weekly close since March 2024 was ₹191.80 on 2 March 2024. ### GPT Healthcare share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹130.96 | +5.1% |
| 1 month ago · 1 Oct 2026 | ₹151.47 | −9.1% |
| 6 months ago · 30 Apr 2026 | ₹138.43 | −0.6% |
| 1 year ago · 31 Oct 2025 | ₹148.64 | −7.4% |
| Earliest and highest weekly close in our records · 2 Mar 2024 | ₹191.80 | −28.2% |
| Lowest weekly close since March 2024, also the 52-week low · 27 Mar 2026 | ₹116.02 | +18.7% |
| 52-week high (weekly close) · 31 Jul 2026 | ₹170.49 | −19.3% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (146 weekly closes from 2 March 2024 to 3 November 2026.)

## What is the latest news on GPT Healthcare? 3 Nov 2026: GPT Healthcare closed at ₹137.66, up 5.1% on the week and down 9.1% on the month. 28 Sep 2026: GPT Healthcare held its results call for April to June 2026. Management guided: Network to approximately 1,000 beds in the next couple of years, with 10-12% annual bed additions and one new hospital every 18 months. ### Earlier

- 30 Jul 2026: ex-date for a dividend of ₹1.50 a share. - Results for April to June 2026: Revenue up 17.8% and profit up 62.5% on a year earlier. - 14 Nov 2025: ex-date for an interim dividend of ₹1 a share. ## What dividend does GPT Healthcare pay? GPT Healthcare paid ₹2.50 a share in regular dividends in the 12 months to 4 November 2026 (2 payments), a yield of 1.82% at the ₹137.66 close on 3 November 2026. The last was a dividend of ₹1.50 a share, ex-date 30 July 2026. ### GPT Healthcare dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 30 Jul 2026 | ₹1.50 | Dividend |
| 14 Nov 2025 | ₹1 | Interim |
| 29 Jul 2025 | ₹1.50 | Dividend |
| 28 Nov 2024 | ₹1 | Interim |
| 18 Jul 2024 | ₹1.50 | Dividend |
| 2 Apr 2024 | ₹1 | Interim |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. GPT Healthcare Ltd paid out 49% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 7 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did GPT Healthcare management say on the latest results call? On the call for April to June 2026, held on 28 September 2026, GPT Healthcare's management guided: Network to approximately 1,000 beds in the next couple of years, with 10-12% annual bed additions and one new hospital every 18 months. > “We do not expect to dilute any further from here.”
> Atul Tantia, on the call for April to June 2026

### What management guided

- Revenue yearly growth of approximately 15-17% over the next 4-5 years. - Consolidated operating margin around 21% after new-hospital losses; mature hospitals around 25%. - Raipur occupancy around 30% by March and profitability around March. - Dum Dum and Salt Lake to reach 70% occupancy in the next couple quarters, Agartala near 60% and Howrah 55%; Jamshedpur starts March/April next year, then goals that occupancy level and 22-23% operating margin over five years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/45891-28-Sep-2026.pdf). (From the call for April to June 2026, 28 September 2026.)

## What to watch in GPT Healthcare's next results? When GPT Healthcare reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Raipur ramp: check whether the March profitability milestone is achieved and quarterly losses taper. - What to check (from the call)
- Raipur ramp: check whether the March profitability milestone is achieved and quarterly losses taper. - Mature-hospital occupancy: check Dum Dum, Salt Lake, Agartala and Howrah against the stated near-term trajectory. - Jamshedpur launch: check the stated start window, consultant build-out and disclosure of initial losses. ## Which stock lists is GPT Healthcare on? GPT Healthcare is on one of our India lists: Dividend stocks. [Dividend stocks Regular dividend yield (%): 1.85](https://www.sectoralpha.in/dividend-stocks-india)

## Is GPT Healthcare profitable? GPT Healthcare Ltd earned ₹13.0 Cr of net profit in the Jun 2026 quarter, +62.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹42.0 Cr. Over 6 years profit has grown 25.0% a year on average. That is 10.3% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr. For the full year, FY26 profit was ₹42.0 Cr (−16.0% on the year before). Why profit moved: revenue changed +17.8% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +6.5% and revenue +18.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does GPT Healthcare make, and is it growing? GPT Healthcare Ltd reported ₹126 Cr of revenue in the Jun 2026 quarter, +17.8% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 6 years it has grown 14.3% a year on average. The last full year, FY26, came in at ₹473 Cr. The last four reported quarters add to ₹491 Cr. FY26 revenue was ₹473 Cr, +16.2% on the year before. Recent pace: the last four quarters grew +18.1% on average, against 14.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +18.0%, against +10.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +0.0%, against +0.0% a year (stabilising). ## How much of every ₹100 of sales does GPT Healthcare keep? GPT Healthcare Ltd's operating margin was 19.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 7 years it has been between 17.0% and 22.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.9 percentage points on the year while gross margin changed +0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is GPT Healthcare's profit turning into cash? Over the last 3 years, 155% of GPT Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹81.0 Cr of operating cash against ₹42.0 Cr of profit. After ₹96.0 Cr of spending on assets, free cash was −₹15.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 155% of profit came in as cash: the cash cycle got 14 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 2.8× depreciation over three years. The next section checks what that spending is building. ## Where does GPT Healthcare's cash go? GPT Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −112 days in FY26, down from −98 days in FY21. It spent ₹176 Cr on assets over the last 3 years. Customers take 16 days to pay, and stock sits for 43 days on average. At FY26 sales of ₹473 Cr, each day of that cycle ties up about ₹1.3 Cr, so roughly −₹145 Cr is tied up in the business at any time. FY26: customers took 16 days to pay and stock sat for 43 days, about 1.4 months of sales sitting as stock, for a full cycle of −112 days, shorter than FY21's −98. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 43 days. Customers pay about 16 days after that. Suppliers are paid at 170 days. Together that makes the −112-day cycle. Spending on assets: ₹176 Cr over the last 3 years, against ₹64.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is GPT Healthcare's P/E ratio, and how does it compare with its own history? GPT Healthcare Ltd's P/E is 23.8×, near the low end of its own history: it has been lower only 6% of the time. Its usual P/E (the middle reading) is 27.5×, over 2.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −15.3% while the price moved −7.4%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the GPT Healthcare business getting better or worse? GPT Healthcare Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 19.8%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does GPT Healthcare earn on its capital? GPT Healthcare Ltd earned a ROCE of 20% in FY26. That is up from a low of 14% in FY21. Its return on capital used (ROIC) is 4.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.9% net margin and 1.02× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 8.9% net margin × 1.02× asset turnover × 1.73× leverage (assets divided by equity) ≈ 15.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 16.0% − 12.0% = +4.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does GPT Healthcare have too much debt? GPT Healthcare Ltd has total debt of ₹91.0 Cr against shareholder equity of ₹269 Cr as of Jun 2026, so its debt is 0.34× its equity. Year by year, that ratio went from 0.50 in FY23 to 0.34 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the GPT Healthcare shareholding pattern? Domestic institutions cut their stake in GPT Healthcare Ltd by 3.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 7.1% of the company. Foreign institutions moved −1.7 points over the same period, to 3.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −3.7 points over 8 quarters, to 7.1%; Foreign institutions: −1.7 points over 8 quarters, to 3.0%; Promoters: +0.0 points over 8 quarters, to 65.6%. Why the owners changed: domestic institutions drove it (−3.7 points), together with foreign institutions (−1.7 points). They reduced their stake. ## How far is GPT Healthcare from balance-sheet trouble? For GPT Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does GPT Healthcare rank in its industry? 61.2 out of 100, rank 6 of 20 in Hospitals, with 81% of the evidence available. GPT Healthcare Ltd scores 61.2 out of 100 against the 20 companies it is compared with in Hospitals, ranking 6. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 15.4 + 18.2 + 18.5 + 9.1 = 61.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is GPT Healthcare compared with? GPT Healthcare ranks 6 of 20 Hospitals companies on the 4-Factor Sector Score, with 61.2 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.1/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23.1 + 14.1 + 12.5 = 80.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.5/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.5 + 11.1 + 13.8 = 68.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.4/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.4 + 12.5 + 11.6 = 62.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. GPT Healthcare Ltd this page GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.2 + 18.5 + 9.1 = 61.2 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.8/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.8 + 8 + 16.7 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 10. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 17.3 + 5.5 + 14.2 = 50.5 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.3 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.7 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.8 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.2 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to GPT Healthcare in size? GPT Healthcare is the 20th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Artemis Medicare Services, Indraprastha Medical Corporation, Dr Agarwals Eye Hospital, KMC Speciality Hospitals (India), Sakar Healthcare and Shalby. It is the smallest. ### Hospitals companies close in size

1. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ₹4,642 crore
2. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) ₹2,802 crore
3. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) ₹2,570 crore
4. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) ₹2,420 crore
5. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) ₹2,102 crore
6. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) ₹1,303 crore
7. GPT Healthcare Ltd ₹1,089 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [Shriram Properties Ltd](https://www.sectoralpha.in/stocks/shriram-properties-ltd) ₹1,091 crore · Realty - Construction & Contracting
2. [Viceroy Hotels Ltd](https://www.sectoralpha.in/stocks/viceroy-hotels-ltd) ₹1,090 crore · Hotels
3. GPT Healthcare Ltd ₹1,089 crore
4. [Raj Rayon Industries Ltd](https://www.sectoralpha.in/stocks/raj-rayon-industries-ltd) ₹1,084 crore · Textiles - Processing/Texturising
5. [SPML Infra Ltd](https://www.sectoralpha.in/stocks/spml-infra-ltd) ₹1,084 crore · Infra - Construction & Contracting

## What else do people ask about GPT Healthcare? ### What is GPT Healthcare's share price today? GPT Healthcare Ltd's share price is ₹137.66, −7.4% over the past year. The whole company is worth ₹1,127 Cr on the market. In the last 52 weeks it traded between ₹116 to ₹170; today it is 40% of the way up from the low, 6.6% below its 200-day average (as of 3 November 2026). ### What were GPT Healthcare's latest quarterly results? GPT Healthcare Ltd reported revenue of ₹126 Cr and net profit of ₹13.0 Cr for the Jun 2026 quarter. Revenue rose 17.8% and profit rose 62.5% compared with a year earlier. Earnings per share were ₹1.55. The operating margin was 19.0%, 3.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is GPT Healthcare's market cap? GPT Healthcare Ltd's market capitalisation is ₹1,127 Cr at a share price of ₹137.66. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is GPT Healthcare performing? GPT Healthcare Ltd's share price has been rising for 20 weeks. In its latest quarter, revenue rose 17.8% and profit rose 62.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 5 weeks running (as of 3 November 2026). ### Will GPT Healthcare's share price go up? This page does not forecast GPT Healthcare Ltd's share price. What it shows instead: the share price is ₹137.66, and it has been rising for 20 weeks. Its P/E of 23.8× is higher than 6% of its own last 3 years (as of 3 November 2026). ### Who owns GPT Healthcare? Promoters own 65.6% of GPT Healthcare Ltd, foreign institutions 3.0%, domestic institutions 7.1% and the public 24.3% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 3.7 percentage points over 8 quarters (as of 3 November 2026). ### Where is GPT Healthcare in its business cycle? GPT Healthcare Ltd's FY26 operating margin was 18.0%, against a 7-year range of 17.0% to 22.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the GPT Healthcare story? The main question: foreign institutions moved −1.7 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is GPT Healthcare a stock worth studying right now? What the numbers show: GPT Healthcare Ltd's results are improving, while its P/E is near the low end of its own history over 2.7 years, higher than only 6% of past readings. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a GPT Healthcare share price forecast for 2026? What management itself guided: Network to approximately 1,000 beds in the next couple of years, with 10-12% annual bed additions and one new hospital every 18 months. ## Lists

- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india

This is research, not advice. We’re not SEBI-registered.